Head to head · SEC data as of July 10, 2026
Amgen
71
Quality score · out of 100
Gilead
92
Quality score · out of 100
Gilead comes in ahead: a quality score of 92 versus 71 for Amgen. Gilead wins on net margin (31% vs 21%), cash generation (FCF) (34.4% vs 23.1%) and earnings growth (127.7% vs 3%). Amgen answers with ROE (84.9% vs 39.2%) and revenue growth (7.5% vs 3.6%).
| Metric | Amgen | Gilead |
|---|---|---|
| Quality score (0-100) | 71 | 92 |
| Net margin | 21% | 31% |
| Gross margin | — | — |
| ROE | 84.9% | 39.2% |
| Net debt/EBITDA | 2.93× | 1.56× |
| FCF margin | 23.1% | 34.4% |
| Revenue growth (annualized) | 7.5% | 3.6% |
| Earnings growth (annualized) | 3% | 127.7% |
TTM metrics with official SEC data, refreshed daily. Bold green marks the winner of each metric. A dash means the metric doesn't apply or isn't reliable.
Amgen. Amgen is one of the world's largest biotech companies. It specializes in biologic medicines —made from living cells— for serious diseases such as cancer and cardiovascular or inflammatory conditions. It has a broad portfolio and a strong dividend.
Gilead. Gilead Sciences is a large U.S. biotech. Its historic business is antivirals: it leads HIV treatment and revolutionized the cure for hepatitis C. It's now trying to diversify into oncology to depend less on a single area.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
What this comparison doesn't tell you
The score measures business quality, not whether the stock is cheap or expensive: the better company can be the worse investment if you overpay. For the valuation verdict, enter each one's current price in the analyzer:
Who has the stronger fundamentals today, Amgen or Gilead?
By the StockSemáforo model (profitability, growth and financial strength, built on official SEC data), Gilead scores higher: 92 versus 71 out of 100. The score is recomputed nightly with the latest filings.
Does that make Gilead the better investment?
No. The score measures business quality, not valuation: an excellent company can trade at an excessive price and be a poor investment at that price. To find out whether it's cheap or expensive, enter its current quote in the StockSemáforo analyzer.
Other comparisons
Pfizer vs Merck · Johnson & Johnson vs Pfizer · Eli Lilly vs AbbVie · UnitedHealth vs CVS Health · See all comparisons →